MyFinsight
Home
Blog
About
Contact
Download
Download image
Total comprehensive
loss
-$167,538K
Unrealized gain on
available-for-sale securities
$257K
Interest income
$23,611K
Net loss
-$167,795K
Total other income
$23,611K
Loss from operations
-$191,406K
Total operating
expenses
$191,406K
Research and development
$151,389K
General and
administrative
$40,017K
Back
Back
Income Statement
source: myfinsight.com
Edgewise Therapeutics, Inc. (EWTX)
Edgewise Therapeutics, Inc. (EWTX)